NasdaqGS:ABSIBiotechs
Assessing Absci (ABSI) Valuation After First Volunteers Dosed in ABS-201 HeadLINE Trial
Absci (ABSI) just crossed an important milestone by dosing the first healthy volunteers in its Phase 1/2a HeadLINE trial for ABS-201, an AI designed antibody targeting androgenetic alopecia and, later, endometriosis.
See our latest analysis for Absci.
The ABS-201 milestone lands after a volatile stretch, with the share price up 8.6 percent over one day and 6.5 percent over seven days, yet still showing a negative 30 day share price return while the 1 year total shareholder return remains...